{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:25:39Z","timestamp":1740108339187,"version":"3.37.3"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T00:00:00Z","timestamp":1572307200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T00:00:00Z","timestamp":1572307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s00228-019-02774-2","type":"journal-article","created":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T20:53:50Z","timestamp":1572468830000},"page":"131-132","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["An unmet medical need vs. regulatory recommendations: how should we treat patients with hyperaldosteronism and advanced chronic kidney disease when surgery is not feasible?"],"prefix":"10.1007","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8033-9482","authenticated-orcid":false,"given":"Ivana","family":"Mika\u010di\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,29]]},"reference":[{"key":"2774_CR1","doi-asserted-by":"publisher","unstructured":"Capelli I, Gasperoni L, Ruggeri M, Donati G, Baraldi O, Sorrenti G, Caletti MT, Aiello V, Cianciolo G, la Manna G (2019) New mineralocorticoid receptor antagonists: update on their use in chronic kidney disease and heart failure. J Nephrol:1\u201312. \nhttps:\/\/doi.org\/10.1007\/s40620-019-00600-7","DOI":"10.1007\/s40620-019-00600-7"},{"issue":"1","key":"2774_CR2","doi-asserted-by":"publisher","first-page":"T125","DOI":"10.1530\/JOE-16-0600","volume":"234","author":"Peter Kolkhof","year":"2017","unstructured":"Kolkhof P, Barfacker L (2017) 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development. The Journal of endocrinology 234 (1):T125\u2013T140","journal-title":"Journal of Endocrinology"},{"issue":"2","key":"2774_CR3","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1007\/s11906-013-0414-8","volume":"16","author":"MI Danjuma","year":"2014","unstructured":"Danjuma MI, Mukherjee I, Makaronidis J, Osula S (2014) Converging indications of aldosterone antagonists (spironolactone and eplerenone): a narrative review of safety profiles. Curr Hypertens Rep 16(2):414. \nhttps:\/\/doi.org\/10.1007\/s11906-013-0414-8","journal-title":"Curr Hypertens Rep"},{"issue":"10","key":"2774_CR4","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341(10):709\u2013717. \nhttps:\/\/doi.org\/10.1056\/NEJM199909023411001","journal-title":"N Engl J Med"},{"issue":"16","key":"2774_CR5","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","volume":"62","author":"CW Yancy","year":"2013","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH et al (2013) 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62(16):e147\u2013e239. \nhttps:\/\/doi.org\/10.1016\/j.jacc.2013.05.019","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"2774_CR6","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","volume":"136","author":"CW Yancy","year":"2017","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM et al (2017) 2017 ACC\/AHA\/HFSA Focused Update of the 2013 ACCF\/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 136(6):e137\u2013ee61. \nhttps:\/\/doi.org\/10.1161\/CIR.0000000000000509","journal-title":"Circulation"},{"key":"2774_CR7","unstructured":"Medicines.org.uk (2019) Spironolactone - summary of product characteristics (SPC) - (eMC). \nhttps:\/\/www.medicines.org.uk\/emc\/ingredient\/36\n\n. Accessed 26 June 2019"},{"key":"2774_CR8","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios - AEMPS (2019) Espironolactona - Summary of Product Characteristics (SPC). \nhttps:\/\/cima.aemps.es\/cima\/publico\/lista.html\n\n. Accessed 26 June 2019"},{"key":"2774_CR9","unstructured":"Swedish Medical Products Agency (2019) Spironolakton -summary of product characteristics (SPC). \nhttps:\/\/lakemedelsverket.se\/LMF\/?q=Spironolakton&type=product\n\n. Accessed 27 June 2019"},{"key":"2774_CR10","unstructured":"Agenzia Italiana del Farmaco - AIFA (2019) Luvion - Riassunto delle caratteristiche del prodotto. \nhttps:\/\/farmaci.agenziafarmaco.gov.it\/aifa\/servlet\/PdfDownloadServlet?pdfFileName=footer_000913_024273_RCP.pdf&retry=0&sys=m0b1l3\n\n. Assessed 26 Aug 2019"},{"key":"2774_CR11","unstructured":"Medicines Evaluation Board (2019) Spironolacton - summary of product characteristics (SPC) \nhttps:\/\/www.geneesmiddeleninformatiebank.nl\/nl\/\n\n. Accessed 30 June 2019"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-019-02774-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-019-02774-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-019-02774-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T00:13:54Z","timestamp":1603844034000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-019-02774-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,29]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["2774"],"URL":"https:\/\/doi.org\/10.1007\/s00228-019-02774-2","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"type":"print","value":"0031-6970"},{"type":"electronic","value":"1432-1041"}],"subject":[],"published":{"date-parts":[[2019,10,29]]},"assertion":[{"value":"15 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The author declares that she has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}